Can Neuropeptide Y Protect the Brain During Stroke in Hypertensive Animals?
NPY13-36 reduced brain damage and improved motor function when given during reperfusion in hypertensive rats after stroke, revealing a new blood vessel protection mechanism.
Quick Facts
What This Study Found
NPY13-36 was injected directly into the brain during either the ischemic phase (while blood flow was blocked) or the reperfusion phase (when blood flow returned). The drug was effective when given during reperfusion, not during ischemia.
During reperfusion, NPY13-36 reduced infarct size (the dead brain area), improved gait, mobility, and sensorimotor function, and restored normal microcirculatory response to nitric oxide synthase blockade. The vasoprotective effect was a new discovery, meaning the drug protected the tiny blood vessels in the brain, not just the neurons.
Key Numbers
- Dose: 10 μg NPY13-36 in 6 μL saline, given into brain ventricles
- Ischemia duration: 90 minutes of middle cerebral artery occlusion
- Drug was effective during reperfusion but not during ischemia
- Reduced infarct area
- Improved gait, mobility, and sensorimotor scores
- Restored microvascular response to NO synthase blockade
How They Did This
Researchers used spontaneously hypertensive rats (SHR), which naturally develop high blood pressure. They blocked the middle cerebral artery for 90 minutes to cause stroke, then allowed blood to return. NPY13-36 (10 micrograms in 6 microliters saline) was injected into the brain ventricles during either ischemia or reperfusion. Brain blood flow was monitored with laser-Doppler. Outcomes included infarct size (TTC staining), behavioral tests, and microvascular responses.
Why This Research Matters
Most stroke neuroprotection research uses healthy young animals, which poorly represents human stroke patients who typically have high blood pressure and other conditions. This study used hypertensive rats, making it more clinically relevant. The discovery of vasoprotection (blood vessel protection) in addition to neuroprotection is a new mechanism that could be important for stroke treatment.
The Bigger Picture
Most stroke neuroprotection studies use healthy young animals, which poorly represents real stroke patients who typically have high blood pressure. Testing in hypertensive animals makes results more clinically relevant.
What This Study Doesn't Tell Us
This was tested in rats, not people. The drug was injected directly into the brain, which is not a practical delivery method for human patients. The sample size is not stated in the abstract. Spontaneously hypertensive rats, while better than healthy rats, still do not fully replicate human stroke. The drug had to be given very shortly after reperfusion, which may not be achievable clinically.
Questions This Raises
- ?Can NPY13-36 be delivered without brain injection?
- ?Would the drug work with a longer delay after reperfusion begins?
- ?Can the vasoprotective mechanism be targeted more specifically?
Trust & Context
- Key Stat:
- Novel vasoprotection discovered First demonstration that NPY13-36 protects brain blood vessels (not just neurons) during stroke recovery in hypertensive animals
- Evidence Grade:
- Rated preliminary: promising animal study in a clinically relevant model, but the drug was injected directly into the brain, which is not practical for human use.
- Study Age:
- Published in 2024. This is early-stage preclinical research contributing to the NPY neuroprotection field.
- Original Title:
- Neuro- and vasoprotective potential of neuropeptide Y Y2 receptor agonist, NPY13-36, against transient focal cerebral ischemia in spontaneously hypertensive rats.
- Published In:
- Neuroscience, 562, 10-23 (2024)
- Authors:
- Przykaza, Łukasz, Domin, Helena, Śmiałowska, Maria, Stanaszek, Luiza, Boguszewski, Paweł M, Kozniewska, Ewa
- Database ID:
- RPEP-09093
Evidence Hierarchy
Frequently Asked Questions
What is NPY13-36?
A fragment of neuropeptide Y that specifically activates Y2 receptors, which are involved in neuroprotection in the brain.
Why use hypertensive rats?
Most stroke patients have high blood pressure. Using hypertensive animals makes the research more relevant to real human stroke than using healthy young animals.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09093APA
Przykaza, Łukasz; Domin, Helena; Śmiałowska, Maria; Stanaszek, Luiza; Boguszewski, Paweł M; Kozniewska, Ewa. (2024). Neuro- and vasoprotective potential of neuropeptide Y Y2 receptor agonist, NPY13-36, against transient focal cerebral ischemia in spontaneously hypertensive rats.. Neuroscience, 562, 10-23. https://doi.org/10.1016/j.neuroscience.2024.10.035
MLA
Przykaza, Łukasz, et al. "Neuro- and vasoprotective potential of neuropeptide Y Y2 receptor agonist, NPY13-36, against transient focal cerebral ischemia in spontaneously hypertensive rats.." Neuroscience, 2024. https://doi.org/10.1016/j.neuroscience.2024.10.035
RethinkPeptides
RethinkPeptides Research Database. "Neuro- and vasoprotective potential of neuropeptide Y Y2 rec..." RPEP-09093. Retrieved from https://rethinkpeptides.com/research/przykaza-2024-neuro-and-vasoprotective-potential
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.